Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders

Pharmacology and Therapeutics

Volumn 166, Issue , 2016, Pages 106-122

  Ganai, Shabir Ahmad ^a   Banday, Shahid ^a   Farooq, Zeenat ^a   Altaf, Mohammad ^a  

^a UNIVERSITY OF KASHMIR   (India)

Author keywords

HAT modulators; HATs; HDACi; HDACs; Histone acetylation; Neurodegenerative diseases

Indexed keywords

HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; REGULATOR PROTEIN; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; P300-CBP-ASSOCIATED FACTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CELL SURVIVAL; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME REGULATION; EPIGENETICS; HISTONE ACETYLATION; HUMAN; HUNTINGTON CHOREA; MEMORY; METABOLIC REGULATION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN HOMEOSTASIS; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; THERAPY EFFECT; TRANSCRIPTION REGULATION; ACETYLATION; ANIMAL; HUNTINGTON DISEASE; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOPHYSIOLOGY;

ACETYLATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HUNTINGTON DISEASE; NEURODEGENERATIVE DISEASES; P300-CBP TRANSCRIPTION FACTORS; PARKINSON DISEASE;

EID: 84978872478     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.07.001     Document Type: Article

References (211)

1. Abel, T., Zukin, R.S., Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol 8 (2008), 57–64.
2. Achour, M., Le Gras, S., Keime, C., Parmentier, F., Lejeune, F.X., Boutillier, A.L.,.. Merienne, K., Neuronal identity genes regulated by super-enhancers are preferentially down-regulated in the striatum of Huntington's disease mice. Hum Mol Genet 24 (2015), 3481–3496.
3. Agranoff, B.W., Davis, R.E., Casola, L., Lim, R., Actinomycin D blocks formation of memory of shock-avoidance in goldfish. Science 158 (1967), 1600–1601.
4. Airaksinen, M.S., Saarma, M., The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3 (2002), 383–394.
5. Ait-Si-Ali, S., Ramirez, S., Barre, F.X., Dkhissi, F., Magnaghi-Jaulin, L., Girault, J.A.,.. Harel-Bellan, A., Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature 396 (1998), 184–186.
6. Alarcon, J.M., Malleret, G., Touzani, K., Vronskaya, S., Ishii, S., Kandel, E.R., Barco, A., Chromatin acetylation, memory, and LTP are impaired in CBP +/− mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42 (2004), 947–959.
7. Allis, C.D., Berger, S.L., Cote, J., Dent, S., Jenuwien, T., Kouzarides, T.,.. Zhang, Y., New nomenclature for chromatin-modifying enzymes. Cell 131 (2007), 633–636.
8. Altaf, M., Saksouk, N., Cote, J., Histone modifications in response to DNA damage. Mutat Res 618 (2007), 81–90.
9. Andrisani, O.M., CREB-mediated transcriptional control. Crit Rev Eukaryot Gene Expr 9 (1999), 19–32.
10. Anne-Laurence, B., Caroline, R., Irina, P., Jean-Philippe, L., Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools. Subcell Biochem 41 (2007), 263–293.
11. Azevedo, F.A., Carvalho, L.R., Grinberg, L.T., Farfel, J.M., Ferretti, R.E., Leite, R.E.,.. Herculano-Houzel, S., Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol 513 (2009), 532–541.
12. Balasubramanyam, K., Altaf, M., Varier, R.A., Swaminathan, V., Ravindran, A., Sadhale, P.P., Kundu, T.K., Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 279 (2004), 33716–33726.
13. Balasubramanyam, K., Swaminathan, V., Ranganathan, A., Kundu, T.K., Small molecule modulators of histone acetyltransferase p300. J Biol Chem 278 (2003), 19134–19140.
14. Balasubramanyam, K., Varier, R.A., Altaf, M., Swaminathan, V., Siddappa, N.B., Ranga, U., Kundu, T.K., Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 279 (2004), 51163–51171.
15. Ballatore, C., Lee, V.M., Trojanowski, J.Q., Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8 (2007), 663–672.
16. Bang, S.R., Ambavade, S.D., Jagdale, P.G., Adkar, P.P., Waghmare, A.B., Ambavade, P.D., Lacosamide reduces HDAC levels in the brain and improves memory: potential for treatment of Alzheimer's disease. Pharmacol Biochem Behav 134:134 (2015), 65–69.
17. Bannister, A.J., Kouzarides, T., Regulation of chromatin by histone modifications. Cell Res 21 (2011), 381–395.
18. Barrett, R.M., Wood, M.A., Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory. Learn Mem 15 (2008), 460–467.
19. Bellet, M.M., Nakahata, Y., Boudjelal, M., Watts, E., Mossakowska, D.E., Edwards, K.A.,.. Sassone-Corsi, P., Pharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1. Proc Natl Acad Sci U S A 110 (2013), 3333–3338.
20. Benito, E., Urbanke, H., Ramachandran, B., Barth, J., Halder, R., Awasthi, A.,.. Fischer, A., HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models. J Clin Invest 125 (2015), 3572–3584.
21. Berger, S.L., The complex language of chromatin regulation during transcription. Nature 447 (2007), 407–412.
22. Black, J.C., Mosley, A., Kitada, T., Washburn, M., Carey, M., The SIRT2 deacetylase regulates autoacetylation of p300. Mol Cell 32 (2008), 449–455.
23. Bourtchouladze, R., Abel, T., Berman, N., Gordon, R., Lapidus, K., Kandel, E.R., Different training procedures recruit either one or two critical periods for contextual memory consolidation, each of which requires protein synthesis and PKA. Learn Mem 5 (1998), 365–374.
24. Bousiges, O., Vasconcelos, A.P., Neidl, R., Cosquer, B., Herbeaux, K., Panteleeva, I.,.. Boutillier, A.L., Spatial memory consolidation is associated with induction of several lysine-acetyltransferase (histone acetyltransferase) expression levels and H2B/H4 acetylation-dependent transcriptional events in the rat hippocampus. Neuropsychopharmacology 35 (2010), 2521–2537.
25. Boutillier, A.L., Trinh, E., Loeffler, J.P., Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J Neurochem 84 (2003), 814–828.
26. Bu, P., Evrard, Y.A., Lozano, G., Dent, S.Y., Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol Cell Biol 27 (2007), 3405–3416.
27. Caccamo, A., Maldonado, M.A., Bokov, A.F., Majumder, S., Oddo, S., CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci 107 (2010), 22687–22692.
28. Calfa, G., Chapleau, C.A., Campbell, S., Inoue, T., Morse, S.J., Lubin, F.D., Pozzo-Miller, L., HDAC activity is required for BDNF to increase quantal neurotransmitter release and dendritic spine density in CA1 pyramidal neurons. Hippocampus 22 (2012), 1493–1500.
29. Cha, J.H., Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23 (2000), 387–392.
30. Chatterjee, S., Mizar, P., Cassel, R., Neidl, R., Selvi, B.R., Mohankrishna, D.V.,.. Boutillier, A.L., A novel activator of CBP/p300 acetyltransferases promotes neurogenesis and extends memory duration in adult mice. J Neurosci 33 (2013), 10698–10712.
31. Chawla, S., Hardingham, G.E., Quinn, D.R., Bading, H., CBP: a signal-regulated transcriptional coactivator controlled by nuclear calcium and CaM kinase IV. Science 281 (1998), 1505–1509.
32. Chen, C.J., Deng, Z., Kim, A.Y., Blobel, G.A., Lieberman, P.M., Stimulation of CREB binding protein nucleosomal histone acetyltransferase activity by a class of transcriptional activators. Mol Cell Biol 21 (2001), 476–487.
33. Chen, Y.C., Gatchel, J.R., Lewis, R.W., Mao, C.A., Grant, P.A., Zoghbi, H.Y., Dent, S.Y., Gcn5 loss-of-function accelerates cerebellar and retinal degeneration in a SCA7 mouse model. Hum Mol Genet 21 (2012), 394–405.
34. Chen, P.S., Peng, G.S., Li, G., Yang, S., Wu, X., Wang, C.C.,.. Hong, J.S., Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11 (2006), 1116–1125.
35. Chen, S.H., Wu, H.M., Ossola, B., Schendzielorz, N., Wilson, B.C., Chu, C.H.,.. Lu, R.B., Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br J Pharmacol 165 (2012), 494–505.
36. Chevillard-Briet, M., Trouche, D., Vandel, L., Control of CBP co-activating activity by arginine methylation. EMBO J 21 (2002), 5457–5466.
37. Chou, S.M., Neuropathology of amyotrophic lateral sclerosis: new perspectives on an old disease. J Formos Med Assoc 96 (1997), 488–498.
38. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M.L., Rehman, M., Walther, T.C.,.. Mann, M., Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325 (2009), 834–840.
39. Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., Chiu, C.-T., Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32 (2009), 591–601.
40. Chun, P., Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res 38 (2015), 933–949.
41. Clement, A.M., Nguyen, M.D., Roberts, E.A., Garcia, M.L., Boillee, S., Rule, M.,.. Cleveland, D.W., Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302 (2003), 113–117.
42. Cong, S.Y., Pepers, B.A., Evert, B.O., Rubinsztein, D.C., Roos, R.A., van Ommen, G.J., Dorsman, J.C., Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Mol Cell Neurosci 30 (2005), 12–23.
43. Creaven, M., Hans, F., Mutskov, V., Col, E., Caron, C., Dimitrov, S., Khochbin, S., Control of the histone-acetyltransferase activity of Tip60 by the HIV-1 transactivator protein, Tat. Biochemistry 38 (1999), 8826–8830.
44. Crepaldi, L., Policarpi, C., Coatti, A., Sherlock, W.T., Jongbloets, B.C., Down, T.A., Riccio, A., Binding of TFIIIC to SINE elements controls the relocation of activity-dependent neuronal genes to transcription factories. PLoS Genet, 9, 2013, e1003699.
45. Dal Piaz, F., Tosco, A., Eletto, D., Piccinelli, A.L., Moltedo, O., Franceschelli, S.,.. De Tommasi, N., The identification of a novel natural activator of p300 histone acetyltranferase provides new insights into the modulation mechanism of this enzyme. Chembiochem 11 (2010), 818–827.
46. Dash, P.K., Orsi, S.A., Moore, A.N., Histone deactylase inhibition combined with behavioral therapy enhances learning and memory following traumatic brain injury. Neuroscience 163 (2009), 1–8.
47. Daujat, S., Bauer, U.M., Shah, V., Turner, B., Berger, S., Kouzarides, T., Crosstalk between CARM1 methylation and CBP acetylation on histone H3. Curr Biol 12 (2002), 2090–2097.
48. Davey, C.A., Sargent, D.F., Luger, K., Maeder, A.W., Richmond, T.J., Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 a resolution. J Mol Biol 319 (2002), 1097–1113.
49. Del Signore, S.J., Amante, D.J., Kim, J., Stack, E.C., Goodrich, S., Cormier, K.,.. Ferrante, R.J., Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph Lateral Scler 10 (2009), 85–94.
50. Denu, J.M., Linking chromatin function with metabolic networks: Sir2 family of NAD(+)-dependent deacetylases. Trends Biochem Sci 28 (2003), 41–48.
51. Didonna, A., Opal, P., The promise and perils of HDAC inhibitors in neurodegeneration. Ann Clin Transl Neurol 2 (2015), 79–101.
52. Dietz, K.C., Casaccia, P., HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol Res 62 (2010), 11–17.
53. Dokmanovic, M., Marks, P.A., Prospects: histone deacetylase inhibitors. J Cell Biochem 96 (2005), 293–304.
54. Dompierre, J.P., Godin, J.D., Charrin, B.C., Cordelieres, F.P., King, S.J., Humbert, S., Saudou, F., Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 27 (2007), 3571–3583.
55. Espinosa, M.C., Rehman, M.A., Chisamore-Robert, P., Jeffery, D., Yankulov, K., GCN5 is a positive regulator of origins of DNA replication in Saccharomyces cerevisiae. PLoS One, 5, 2010, e8964.
56. Farooq, Z., Banday, S., Pandita, T.K., Altaf, M., The many faces of histone H3K79 methylation. Mutat Res 768 (2016), 46–52.
57. Feil, R., Fraga, M.F., Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet 13 (2011), 97–109.
58. Feng, H.L., Leng, Y., Ma, C.H., Zhang, J., Ren, M., Chuang, D.M., Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 155 (2008), 567–572.
59. Ferrante, R.J., Kubilus, J.K., Lee, J., Ryu, H., Beesen, A., Zucker, B.,.. Hersch, S.M., Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23 (2003), 9418–9427.
60. Fischer, A., Epigenetic memory: the Lamarckian brain. EMBO J 33 (2014), 945–967.
61. Fischer, A., Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?. Neuropharmacology 80 (2014), 95–102.
62. Fischer, A., Sananbenesi, F., Mungenast, A., Tsai, L.H., Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 31 (2010), 605–617.
63. Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., Tsai, L.H., Recovery of learning and memory is associated with chromatin remodelling. Nature 447 (2007), 178–182.
64. Flood, J.F., Rosenzweig, M.R., Bennett, E.L., Orme, A.E., The influence of duration of protein synthesis inhibition on memory. Physiol Behav 10 (1973), 555–562.
65. Ganai, S.A., Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance. Pharm Biol, 2016, 1–10.
66. Ganai, S.A., Panobinostat: the small molecule metalloenzyme inhibitor with marvelous anticancer activity. Curr Top Med Chem 16 (2016), 427–434.
67. Ganai, S.A., Ramadoss, M., Mahadevan, V., Histone deacetylase (HDAC) inhibitors — emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration. Curr Neuropharmacol 14 (2016), 55–71.
68. Ganai, S.A., Shanmugam, K., Mahadevan, V., Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of class II HDAC isoforms. J Biomol Struct Dyn 33 (2015), 374–387.
69. Gardian, G., Browne, S.E., Choi, D.K., Klivenyi, P., Gregorio, J., Kubilus, J.K.,.. Beal, M.F., Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280 (2005), 556–563.
70. Gardian, G., Yang, L., Cleren, C., Calingasan, N.Y., Klivenyi, P., Beal, M.F., Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neruomol Med 5 (2004), 235–241.
71. Gaub, P., Joshi, Y., Wuttke, A., Naumann, U., Schnichels, S., Heiduschka, P., Di Giovanni, S., The histone acetyltransferase p300 promotes intrinsic axonal regeneration. Brain 134 (2011), 2134–2148.
72. Gehrking, K.M., Andresen, J.M., Duvick, L., Lough, J., Zoghbi, H.Y., Orr, H.T., Partial loss of Tip60 slows mid-stage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model. Hum Mol Genet 20 (2011), 2204–2212.
73. Govindarajan, N., Rao, P., Burkhardt, S., Sananbenesi, F., Schluter, O.M., Bradke, F.,.. Fischer, A., Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol Med 5 (2013), 52–63.
74. Gregoire, S., Xiao, L., Nie, J., Zhang, X., Xu, M., Li, J.,.. Yang, X.J., Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol 27 (2007), 1280–1295.
75. Grossman, S.R., Deato, M.E., Brignone, C., Chan, H.M., Kung, A.L., Tagami, H.,.. Livingston, D.M., Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300 (2003), 342–344.
76. Guan, Z., Giustetto, M., Lomvardas, S., Kim, J.H., Miniaci, M.C., Schwartz, J.H.,.. Kandel, E.R., Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 111 (2002), 483–493.
77. Guan, J.S., Haggarty, S.J., Giacometti, E., Dannenberg, J.H., Joseph, N., Gao, J.,.. Tsai, L.H., HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459 (2009), 55–60.
78. Hamamori, Y., Sartorelli, V., Ogryzko, V., Puri, P.L., Wu, H.Y., Wang, J.Y.,.. Kedes, L., Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 96 (1999), 405–413.
79. Hardingham, G.E., Chawla, S., Cruzalegui, F.H., Bading, H., Control of recruitment and transcription-activating function of CBP determines gene regulation by NMDA receptors and L-type calcium channels. Neuron 22 (1999), 789–798.
80. Harrison, I.F., Crum, W.R., Vernon, A.C., Dexter, D.T., Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors. Br J Pharmacol 172 (2015), 4200–4215.
81. Herskovits, A.Z., Guarente, L., SIRT1 in neurodevelopment and brain senescence. Neuron 81 (2014), 471–483.
82. Hockly, E., Richon, V.M., Woodman, B., Smith, D.L., Zhou, X., Rosa, E.,.. Bates, G.P., Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 100 (2003), 2041–2046.
83. Hodges, A., Strand, A.D., Aragaki, A.K., Kuhn, A., Sengstag, T., Hughes, G.,.. Luthi-Carter, R., Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15 (2006), 965–977.
84. Hoshino, M., Tagawa, K., Okuda, T., Murata, M., Oyanagi, K., Arai, N.,.. Okazawa, H., Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein. J Neurochem 87 (2003), 257–267.
85. Hsieh, J., Nakashima, K., Kuwabara, T., Mejia, E., Gage, F.H., Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci U S A 101 (2004), 16659–16664.
86. Ittner, L.M., Gotz, J., Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12 (2011), 65–72.
87. Iwata, A., Riley, B.E., Johnston, J.A., Kopito, R.R., HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 280 (2005), 40282–40292.
88. Jaenisch, R., Bird, A., Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33:Suppl (2003), 245–254.
89. Janssen, C., Schmalbach, S., Boeselt, S., Sarlette, A., Dengler, R., Petri, S., Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 69 (2010), 573–581.
90. Jeong, H., Then, F., Melia, T.J., Mazzulli, J.R., Cui, L., Savas, J.N.,.. Krainc, D., Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137 (2009), 60–72.
91. Jia, H., Morris, C.D., Williams, R.M., Loring, J.F., Thomas, E.A., HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation. Proc Natl Acad Sci 112 (2015), E56–E64.
92. Jiang, H., Nucifora, F.C. Jr., Ross, C.A., DeFranco, D.B., Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum Mol Genet 12 (2003), 1–12.
93. Jiang, H., Poirier, M.A., Liang, Y., Pei, Z., Weiskittel, C.E., Smith, W.W.,.. Ross, C.A., Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol Dis 23 (2006), 543–551.
94. Johnson, A.A., Sarthi, J., Pirooznia, S.K., Reube, W., Elefant, F., Increasing Tip60 HAT levels rescues axonal transport defects and associated behavioral phenotypes in a Drosophila Alzheimer's disease model. J Neurosci 33 (2013), 7535–7547.
95. Kalkhoven, E., Roelfsema, J.H., Teunissen, H., den Boer, A., Ariyurek, Y., Zantema, A.,.. Peters, D.J., Loss of CBP acetyltransferase activity by PHD finger mutations in Rubinstein–Taybi syndrome. Hum Mol Genet 12 (2003), 441–450.
96. Karmodiya, K., Anamika, K., Muley, V., Pradhan, S.J., Bhide, Y., Galande, S., Camello, a novel family of histone acetyltransferases that acetylate histone H4 and is essential for zebrafish development. Sci Rep, 4, 2014, 6076.
97. Kawasaki, H., Schiltz, L., Chiu, R., Itakura, K., Taira, K., Nakatani, Y., Yokoyama, K.K., ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylation. Nature 405 (2000), 195–200.
98. Kim, M.S., Akhtar, M.W., Adachi, M., Mahgoub, M., Bassel-Duby, R., Kavalali, E.T.,.. Monteggia, L.M., An essential role for histone deacetylase 4 in synaptic plasticity and memory formation. J Neurosci 32 (2012), 10879–10886.
99. Kim, D., Frank, C.L., Dobbin, M.M., Tsunemoto, R.K., Tu, W., Peng, P.L.,.. Tsai, L.H., Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron 60 (2008), 803–817.
100. Kontopoulos, E., Parvin, J.D., Feany, M.B., Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15 (2006), 3012–3023.
101. Kornberg, R.D., Chromatin structure: a repeating unit of histones and DNA. Science 184 (1974), 868–871.
102. Kotian, S., Liyanarachchi, S., Zelent, A., Parvin, J.D., Histone deacetylases 9 and 10 are required for homologous recombination. J Biol Chem 286 (2011), 7722–7726.
103. Kouzarides, T., Chromatin modifications and their function. Cell 128 (2007), 693–705.
104. Kung, A.L., Rebel, V.I., Bronson, R.T., Ch'ng, L.-E., Sieff, C.A., Livingston, D.M., Yao, T.-P., Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 14 (2000), 272–277.
105. Lau, O.D., Kundu, T.K., Soccio, R.E., Ait-Si-Ali, S., Khalil, E.M., Vassilev, A.,.. Cole, P.A., HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 5 (2000), 589–595.
106. Lazo-Gómez, R., Ramírez-Jarquín, U.N., Tovar-y-Romo, L.B., Tapia, R., Histone deacetylases and their role in motor neuron degeneration. Front Cell Neurosci, 7, 2013, 243.
107. Lee, S., Lee, B., Lee, J.W., Lee, S.K., Retinoid signaling and neurogenin2 function are coupled for the specification of spinal motor neurons through a chromatin modifier CBP. Neuron 62 (2009), 641–654.
108. Legube, G., Trouche, D., Regulating histone acetyltransferases and deacetylases. EMBO Rep 4 (2003), 944–947.
109. Levenson, J.M., O'Riordan, K.J., Brown, K.D., Trinh, M.A., Molfese, D.L., Sweatt, J.D., Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem 279 (2004), 40545–40559.
110. Li, F., Macfarlan, T., Pittman, R.N., Chakravarti, D., Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J Biol Chem 277 (2002), 45004–45012.
111. Li, Q.J., Yang, S.H., Maeda, Y., Sladek, F.M., Sharrocks, A.D., Martins-Green, M., MAP kinase phosphorylation-dependent activation of Elk-1 leads to activation of the co-activator p300. EMBO J 22 (2003), 281–291.
112. Lin, W., Zhang, Z., Chen, C.H., Behringer, R.R., Dent, S.Y., Proper Gcn5 histone acetyltransferase expression is required for normal anteroposterior patterning of the mouse skeleton. Develop Growth Differ 50 (2008), 321–330.
113. Linares, L.K., Kiernan, R., Triboulet, R., Chable-Bessia, C., Latreille, D., Cuvier, O.,.. Benkirane, M., Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol 9 (2007), 331–338.
114. Liu, J., Casaccia, P., Epigenetic regulation of oligodendrocyte identity. Trends Neurosci 33 (2010), 193–201.
115. Lois, C., Garcia-Verdugo, J.M., Alvarez-Buylla, A., Chain migration of neuronal precursors. Science 271 (1996), 978–981.
116. Lopez-Atalaya, J.P., Barco, A., Can changes in histone acetylation contribute to memory formation?. Trends Genet 30 (2014), 529–539.
117. Lopez-Atalaya, J.P., Ciccarelli, A., Viosca, J., Valor, L.M., Jimenez-Minchan, M., Canals, S.,.. Barco, A., CBP is required for environmental enrichment-induced neurogenesis and cognitive enhancement. EMBO J 30 (2011), 4287–4298.
118. Lopez-Atalaya, J.P., Gervasini, C., Mottadelli, F., Spena, S., Piccione, M., Scarano, G.,.. Larizza, L., Histone acetylation deficits in lymphoblastoid cell lines from patients with Rubinstein–Taybi syndrome. J Med Genet 49 (2012), 66–74.
119. Lopez-Atalaya, J.P., Ito, S., Valor, L.M., Benito, E., Barco, A., Genomic targets, and histone acetylation and gene expression profiling of neural HDAC inhibition. Nucleic Acids Res 41 (2013), 8072–8084.
120. Luger, K., Mader, A.W., Richmond, R.K., Sargent, D.F., Richmond, T.J., Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389 (1997), 251–260.
121. Lundby, A., Lage, K., Weinert, B.T., Bekker-Jensen, D.B., Secher, A., Skovgaard, T.,.. Olsen, J.V., Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns. Cell Rep 2 (2012), 419–431.
122. Maddox, S.A., Watts, C.S., Doyère, V., Schafe, G.E., A naturally-occurring histone acetyltransferase inhibitor derived from Garcinia indica impairs newly acquired and reactivated fear memories. PLoS One, 8, 2013, e54463.
123. Majdzadeh, N., Wang, L., Morrison, B.E., Bassel-Duby, R., Olson, E.N., D'Mello, S.R., HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol 68 (2008), 1076–1092.
124. Majid, T., Griffin, D., Criss Ii, Z., Jarpe, M., Pautler, R.G., Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice. Alzheimers Dement 1 (2015), 170–181.
125. Mantelingu, K., Kishore, A.H., Balasubramanyam, K., Kumar, G.V., Altaf, M., Swamy, S.N.,.. Kundu, T.K., Activation of p300 histone acetyltransferase by small molecules altering enzyme structure: probed by surface-enhanced Raman spectroscopy. J Phys Chem B 111 (2007), 4527–4534.
126. Marek, R., Coelho, C.M., Sullivan, R.K., Baker-Andresen, D., Li, X., Ratnu, V.,.. Bredy, T.W., Paradoxical enhancement of fear extinction memory and synaptic plasticity by inhibition of the histone acetyltransferase p300. J Neurosci 31 (2011), 7486–7491.
127. Martinez-Cerdeno, V., Lemen, J.M., Chan, V., Wey, A., Lin, W., Dent, S.R., Knoepfler, P.S., N-Myc and GCN5 regulate significantly overlapping transcriptional programs in neural stem cells. PLoS One, 7, 2012, e39456.
128. Mattson, M.P., Pathways towards and away from Alzheimer's disease. Nature 430 (2004), 631–639.
129. Mayeux, R., Epidemiology of neurodegeneration. Annu Rev Neurosci 26 (2003), 81–104.
130. Mehra-Chaudhary, R., Matsui, H., Raghow, R., Msx3 protein recruits histone deacetylase to down-regulate the Msx1 promoter. Biochem J 353 (2001), 13–22.
131. Merson, T.D., Dixon, M.P., Collin, C., Rietze, R.L., Bartlett, P.F., Thomas, T., Voss, A.K., The transcriptional coactivator Querkopf controls adult neurogenesis. J Neurosci 26 (2006), 11359–11370.
132. Michan, S., Li, Y., Chou, M.M., Parrella, E., Ge, H., Long, J.M.,.. Longo, V.D., SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci 30 (2010), 9695–9707.
133. Miller, K.M., Tjeertes, J.V., Coates, J., Legube, G., Polo, S.E., Britton, S., Jackson, S.P., Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 17 (2010), 1144–1151.
134. Morrison, B.E., Majdzadeh, N., Zhang, X., Lyles, A., Bassel-Duby, R., Olson, E.N., D'Mello, S.R., Neuroprotection by histone deacetylase-related protein. Mol Cell Biol 26 (2006), 3550–3564.
135. Mottamal, M., Zheng, S., Huang, T.L., Wang, G., Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20 (2015), 3898–3941.
136. Nakashima, K., Yanagisawa, M., Arakawa, H., Kimura, N., Hisatsune, T., Kawabata, M.,.. Taga, T., Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science 284 (1999), 479–482.
137. Neidl, R., Schneider, A., Bousiges, O., Majchrzak, M., Barbelivien, A., de Vasconcelos, A.P., Dorgans, K., Late-life Environmental Enrichment Induces Acetylation Events and Nuclear Factor kappaB-dependent Regulations in the Hippocampus of Aged Rats Showing Improved Plasticity and Learning, Vol. 36, 2016, 4351–4361.
138. Nguyen, P.V., Abel, T., Kandel, E.R., Requirement of a critical period of transcription for induction of a late phase of LTP. Science 265 (1994), 1104–1107.
139. Nguyen, L., Humbert, S., Saudou, F., Chariot, A., Elongator — an emerging role in neurological disorders. Trends Mol Med 16 (2010), 1–6.
140. Oike, Y., Hata, A., Mamiya, T., Kaname, T., Noda, Y., Suzuki, M.,.. Yamamura, K., Truncated CBP protein leads to classical Rubinstein–Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum Mol Genet 8 (1999), 387–396.
141. Orrell, R.W., King, A.W., Hilton, D.A., Campbell, M.J., Lane, R.J., de Belleroche, J.S., Familial amyotrophic lateral sclerosis with a point mutation of SOD-1: intrafamilial heterogeneity of disease duration associated with neurofibrillary tangles. J Neurol Neurosurg Psychiatry 59 (1995), 266–270.
142. Outeiro, T.F., Kontopoulos, E., Altmann, S.M., Kufareva, I., Strathearn, K.E., Amore, A.M.,.. Kazantsev, A.G., Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317 (2007), 516–519.
143. Pandey, U.B., Nie, Z., Batlevi, Y., McCray, B.A., Ritson, G.P., Nedelsky, N.B.,.. Taylor, J.P., HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447 (2007), 859–863.
144. Pedre, X., Mastronardi, F., Bruck, W., Lopez-Rodas, G., Kuhlmann, T., Casaccia, P., Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions. J Neurosci 31 (2011), 3435–3445.
145. Peixoto, L., Abel, T., The role of histone acetylation in memory formation and cognitive impairments. Neuropsychopharmacology 38 (2013), 62–76.
146. Peleg, S., Sananbenesi, F., Zovoilis, A., Burkhardt, S., Bahari-Javan, S., Agis-Balboa, R.C.,.. Fischer, A., Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328 (2010), 753–756.
147. Perez-Campo, F.M., Costa, G., Lie, A.L.M., Stifani, S., Kouskoff, V., Lacaud, G., MOZ-mediated repression of p16(INK) (4) (a) is critical for the self-renewal of neural and hematopoietic stem cells. Stem Cells 32 (2014), 1591–1601.
148. Petri, S., Kiaei, M., Kipiani, K., Chen, J., Calingasan, N.Y., Crow, J.P., Beal, M.F., Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22 (2006), 40–49.
149. Pfister, J.A., Ma, C., Morrison, B.E., D'Mello, S.R., Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS One, 3, 2008, e4090.
150. Piekarz, R.L., Frye, R., Turner, M., Wright, J.J., Allen, S.L., Kirschbaum, M.H.,.. Bates, S.E., Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (2009), 5410–5417.
151. Pirooznia, S.K., Elefant, F., Modulating epigenetic HAT activity : a promising therapeutic option for neurological disease ?. J Mol Cloning Genet Recombination 1 (2012), 1–3.
152. Pirooznia, S.K., Elefant, F., Targeting specific HATs for neurodegenerative disease treatment: translating basic biology to therapeutic possibilities. Front Cell Neurosci, 7, 2013, 30.
153. Pirooznia, S.K., Chiu, K., Chan, M.T., Zimmerman, J.E., Elefant, F., Epigenetic regulation of axonal growth of Drosophila pacemaker cells by histone acetyltransferase tip60 controls sleep. Genetics 192 (2012), 1327–1345.
154. Pirooznia, S.K., Sarthi, J., Johnson, A.A., Toth, M.S., Chiu, K., Koduri, S., Elefant, F., Tip60 HAT activity mediates APP induced lethality and apoptotic cell death in the CNS of a Drosophila Alzheimer's disease model. PLoS One, 7, 2012, e41776.
155. Pokholok, D.K., Harbison, C.T., Levine, S., Cole, M., Hannett, N.M., Lee, T.I.,.. Young, R.A., Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 122 (2005), 517–527.
156. Qin, S., Parthun, M.R., Histone H3 and the histone acetyltransferase Hat1p contribute to DNA double-strand break repair. Mol Cell Biol 22 (2002), 8353–8365.
157. Qing, H., He, G., Ly, P.T., Fox, C.J., Staufenbiel, M., Cai, F.,.. Song, W., Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 205 (2008), 2781–2789.
158. Renthal, W., Maze, I., Krishnan, V., Covington, H.E. 3rd, Xiao, G., Kumar, A.,.. Nestler, E.J., Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 56 (2007), 517–529.
159. Richman, R., Chicoine, L.G., Collini, M.P., Cook, R.G., Allis, C.D., Micronuclei and the cytoplasm of growing Tetrahymena contain a histone acetylase activity which is highly specific for free histone H4. J Cell Biol 106 (1988), 1017–1026.
160. Ricobaraza, A., Cuadrado-Tejedor, M., Perez-Mediavilla, A., Frechilla, D., Del Rio, J., Garcia-Osta, A., Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 34 (2009), 1721–1732.
161. Rochefort, C., Gheusi, G., Vincent, J.D., Lledo, P.M., Enriched odor exposure increases the number of newborn neurons in the adult olfactory bulb and improves odor memory. J Neurosci 22 (2002), 2679–2689.
162. Rouaux, C., Jokic, N., Mbebi, C., Boutillier, S., Loeffler, J.P., Boutillier, A.L., Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 22 (2003), 6537–6549.
163. Rouaux, C., Panteleeva, I., Rene, F., Gonzalez de Aguilar, J.L., Echaniz-Laguna, A., Dupuis, L.,.. Loeffler, J.P., Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci 27 (2007), 5535–5545.
164. Ryu, H., Smith, K., Camelo, S.I., Carreras, I., Lee, J., Iglesias, A.H.,.. Ferrante, R.J., Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93 (2005), 1087–1098.
165. Sadri-Vakili, G., Bouzou, B., Benn, C.L., Kim, M.O., Chawla, P., Overland, R.P.,.. Cha, J.H., Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum Mol Genet 16 (2007), 1293–1306.
166. Saha, R.N., Pahan, K., HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 13 (2006), 539–550.
167. Sarthi, J., Elefant, F., dTip60 HAT activity controls synaptic bouton expansion at the Drosophila neuromuscular junction. PLoS One, 6, 2011, e26202.
168. Sasakawa, Y., Naoe, Y., Sogo, N., Inoue, T., Sasakawa, T., Matsuo, M.,.. Mutoh, S., Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 69 (2005), 603–616.
169. Sbardella, G., Castellano, S., Vicidomini, C., Rotili, D., Nebbioso, A., Miceli, M.,.. Mai, A., Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. Bioorg Med Chem Lett 18 (2008), 2788–2792.
170. Schneider, A., Chatterjee, S., Bousiges, O., Selvi, B.R., Swaminathan, A., Cassel, R.,.. Boutillier, A.L., Acetyltransferases (HATs) as targets for neurological therapeutics. Neurotherapeutics 10 (2013), 568–588.
171. Scott, E.K., Lee, T., Luo, L., Enok encodes a Drosophila putative histone acetyltransferase required for mushroom body neuroblast proliferation. Curr Biol 11 (2001), 99–104.
172. Selvi, B.R., Cassel, J.C., Kundu, T.K., Boutillier, A.L., Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases. Biochim Biophys Acta 1799 (2010), 840–853.
173. Selvi, B.R., Jagadeesan, D., Suma, B.S., Nagashankar, G., Arif, M., Balasubramanyam, K.,.. Kundu, T.K., Intrinsically fluorescent carbon nanospheres as a nuclear targeting vector: delivery of membrane-impermeable molecule to modulate gene expression in vivo. Nano Lett 8 (2008), 3182–3188.
174. Sen, N., Hara, M.R., Kornberg, M.D., Cascio, M.B., Bae, B.I., Shahani, N.,.. Sawa, A., Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol 10 (2008), 866–873.
175. Sheikh, B.N., Crafting the brain — role of histone acetyltransferases in neural development and disease. Cell Tissue Res 356 (2014), 553–573.
176. Shen, W.F., Krishnan, K., Lawrence, H.J., Largman, C., The HOX homeodomain proteins block CBP histone acetyltransferase activity. Mol Cell Biol 21 (2001), 7509–7522.
177. Singh, N., Lorbeck, M.T., Zervos, A., Zimmerman, J., Elefant, F., The histone acetyltransferase Elp3 plays in active role in the control of synaptic bouton expansion and sleep in Drosophila. J Neurochem 115 (2010), 493–504.
178. Soliman, M.L., Rosenberger, T.A., Acetate supplementation increases brain histone acetylation and inhibits histone deacetylase activity and expression. Mol Cell Biochem 352 (2011), 173–180.
179. Song, C., Kanthasamy, A., Anantharam, V., Sun, F., Kanthasamy, A.G., Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. Mol Pharmacol 77 (2010), 621–632.
180. Soutoglou, E., Viollet, B., Vaxillaire, M., Yaniv, M., Pontoglio, M., Talianidis, I., Transcription factor-dependent regulation of CBP and P/CAF histone acetyltransferase activity. EMBO J 20 (2001), 1984–1992.
181. Stanton, P.K., Sarvey, J.M., Blockade of long-term potentiation in rat hippocampal CA1 region by inhibitors of protein synthesis. J Neurosci 4 (1984), 3080–3088.
182. Steffan, J.S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B.L.,.. Thompson, L.M., Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413 (2001), 739–743.
183. Sterner, D.E., Berger, S.L., Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 64 (2000), 435–459.
184. Stiles, J., Jernigan, T.L., The basics of brain development. Neuropsychol Rev 20 (2010), 327–348.
185. Strahl, B.D., Allis, C.D., The language of covalent histone modifications. Nature 403 (2000), 41–45.
186. Sugars, K.L., Rubinsztein, D.C., Transcriptional abnormalities in Huntington disease. Trends Genet 19 (2003), 233–238.
187. Sun, Y., Nadal-Vicens, M., Misono, S., Lin, M.Z., Zubiaga, A., Hua, X.,.. Greenberg, M.E., Neurogenin promotes neurogenesis and inhibits glial differentiation by independent mechanisms. Cell 104 (2001), 365–376.
188. Tanaka, Y., Naruse, I., Hongo, T., Xu, M., Nakahata, T., Maekawa, T., Ishii, S., Extensive brain hemorrhage and embryonic lethality in a mouse null mutant of CREB-binding protein. Mech Dev 95 (2000), 133–145.
189. Tanzi, R.E., Bertram, L., Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120 (2005), 545–555.
190. Thomas, E.A., Coppola, G., Desplats, P.A., Tang, B., Soragni, E., Burnett, R.,.. Gottesfeld, J.M., The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci U S A 105 (2008), 15564–15569.
191. Thomas, T., Voss, A.K., Chowdhury, K., Gruss, P., Querkopf, a MYST family histone acetyltransferase, is required for normal cerebral cortex development. Development 127 (2000), 2537–2548.
192. Thompson, P.R., Wang, D., Wang, L., Fulco, M., Pediconi, N., Zhang, D.,.. Cole, P.A., Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol 11 (2004), 308–315.
193. Valor, L.M., Guiretti, D., Lopez-Atalaya, J.P., Barco, A., Genomic landscape of transcriptional and epigenetic dysregulation in early onset polyglutamine disease. J Neurosci 33 (2013), 10471–10482.
194. Valor, L.M., Pulopulos, M.M., Jimenez-Minchan, M., Olivares, R., Lutz, B., Barco, A., Ablation of CBP in forebrain principal neurons causes modest memory and transcriptional defects and a dramatic reduction of histone acetylation but does not affect cell viability. J Neurosci 31 (2011), 1652–1663.
195. Valor, L.M., Viosca, J., Lopez-Atalaya, J.P., Barco, A., Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders. Curr Pharm Des 19 (2013), 5051–5064.
196. Vecsey, C.G., Hawk, J.D., Lattal, K.M., Stein, J.M., Fabian, S.A., Attner, M.A.,.. Wood, M.A., Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB: CBP-dependent transcriptional activation. J Neurosci 27 (2007), 6128–6140.
197. Venkatraman, A., Hu, Y.S., Didonna, A., Cvetanovic, M., Krbanjevic, A., Bilesimo, P., Opal, P., The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1. Hum Mol Genet 23 (2014), 3733–3745.
198. Vernarecci, S., Tosi, F., Filetici, P., Tuning acetylated chromatin with HAT inhibitors: a novel tool for therapy. Epigenetics 5 (2010), 105–111.
199. Ververis, K., Hiong, A., Karagiannis, T.C., Licciardi, P.V., Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7 (2013), 47–60.
200. Viosca, J., Lopez-Atalaya, J.P., Olivares, R., Eckner, R., Barco, A., Syndromic features and mild cognitive impairment in mice with genetic reduction on p300 activity: differential contribution of p300 and CBP to Rubinstein–Taybi syndrome etiology. Neurobiol Dis 37 (2010), 186–194.
201. Wang, J., Chen, J., SIRT1 regulates autoacetylation and histone acetyltransferase activity of TIP60. J Biol Chem 285 (2010), 11458–11464.
202. Wang, Y., Wang, X., Liu, L., Wang, X., HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells. Neurosci Lett 467 (2009), 212–216.
203. Wang, J., Weaver, I.C., Gauthier-Fisher, A., Wang, H., He, L., Yeomans, J.,.. Miller, F.D., CBP histone acetyltransferase activity regulates embryonic neural differentiation in the normal and Rubinstein–Taybi syndrome brain. Dev Cell 18 (2010), 114–125.
204. Wei, W., Coelho, C.M., Li, X., Marek, R., Yan, S., Anderson, S.,.. Bredy, T.W., p300/CBP-associated factor selectively regulates the extinction of conditioned fear. J Neurosci 32 (2012), 11930–11941.
205. Wood, M.A., Kaplan, M.P., Park, A., Blanchard, E.J., Oliveira, A.M., Lombardi, T.L., Abel, T., Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn Mem 12 (2005), 111–119.
206. Wu, X., Chen, P.S., Dallas, S., Wilson, B., Block, M.L., Wang, C.C.,.. Hong, J.S., Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 11 (2008), 1123–1134.
207. Ximenes, J.C., Neves, K.R.T., Leal, L.K.A.M., do Carmo, M.R.S., Brito, G.A.d.C., Naffah-Mazzacoratti, M.d.a.G.,.. Viana, G.S., Valproic acid neuroprotection in the 6-OHDA model of Parkinsons disease is possibly related to its anti-inflammatory and HDAC inhibitory properties. J Neurodegener Dis, 2015, 2015, 14.
208. Xu, W., Edmondson, D.G., Evrard, Y.A., Wakamiya, M., Behringer, R.R., Roth, S.Y., Loss of Gcn5l2 leads to increased apoptosis and mesodermal defects during mouse development. Nat Genet 26 (2000), 229–232.
209. Yamauchi, T., Yamauchi, J., Kuwata, T., Tamura, T., Yamashita, T., Bae, N.,.. Nakatani, Y., Distinct but overlapping roles of histone acetylase PCAF and of the closely related PCAF-B/GCN5 in mouse embryogenesis. Proc Natl Acad Sci U S A 97 (2000), 11303–11306.
210. Yao, T.P., Oh, S.P., Fuchs, M., Zhou, N.D., Ch'ng, L.E., Newsome, D.,.. Eckner, R., Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93 (1998), 361–372.
211. Zeng, L., Zhou, M.M., Bromodomain: an acetyl-lysine binding domain. FEBS Lett 513 (2002), 124–128.